Actively Recruiting
Observational Study of Cibinqo Abrocitinib Tablets for Treating Moderate to Severe Atopic Dermatitis in Patients 12 Years and Older in Korea
Led by Pfizer · Updated on 2025-12-09
1100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Cibinqo Tablet Abrocitinib for treating moderate to severe atopic dermatitis AD, a long-lasting itchy red rash caused by a skin reaction. This is a non-interventional, observational post-marketing surveillance study conducted in Korea with about 3000 participants aged 12 years and older who have been diagnosed with moderate to severe AD and are prescribed Cibinqo according to approved guidelines. Participants will take Cibinqo tablets as prescribed in routine clinical practice, with no mandatory fixed visit schedule. Investigators will collect and record data from each patient during their treatment period, following approved dosage and administration. The study aims to observe participants for up to one year from the first treatment to assess safety and effectiveness in real-world settings. Participants will have their experiences recorded in case report forms without additional mandatory procedures. Researchers will monitor adverse events, serious adverse events, and specific safety concerns up to 52 weeks after starting treatment. Effectiveness will be measured by improvements in skin condition and itch severity over 12 and 52 weeks. The total participation time depends on the patients treatment course and monitoring needs.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here